Pharmacokinetic-dynamic relationship of cisplatin in vitro: simulation of an i.v. bolus and 3 h and 20 h infusion.

The profiles of an i.v. bolus and 3 h and 20 h infusion of cisplatin (CDDP) were simulated in vitro by using a culture of the IGROV1 human ovarian cancer cell line. Disappearance of pharmacologically active unbound CDDP was accomplished by adding human albumin to the medium. Total and unbound CDDP and CDDP-DNA adduct levels were quantitated by atomic absorption spectroscopy (AAS), and tumour cell survival was measured by the clonogenic assay. The design of the experiment resulted in non-significant differences in the magnitude of the area under the concentration-time curve (AUC) of unbound CDDP between the three dose-input functions (AUC i.v. bolus, 6.34 +/- 0.36; 3 h infusion, 6.35 +/- 0.59; and 20 h infusion, 6.76 +/- 0.40 micrograms h ml-1). Also, the differences between the area under the CDDP-DNA adduct-time curves (AUA) of the three dose-input functions were not significant. The initial rate of decline of the CDDP-DNA adduct-time curve was significantly higher for the i.v. bolus and 3 h infusion than for the 20 h infusion. There was a log-linear relationship between the AUC of unbound CDDP and cell survival. These relationships were not significantly different between the three dose-input functions. Variation in the rate of input of CDDP leads to differences in the shape of the AUC and AUA without significant effects on cell survival.

[1]  J. da Silva,et al.  Drug-related chromosomal changes in chemoresistant human ovarian carcinoma cells. , 1989, Cancer genetics and cytogenetics.

[2]  Phase I trial of a cisplatin-albumin complex for the treatment of cancer of the head and neck. , 1992, British journal of clinical pharmacology.

[3]  N. Vogelzang Continuous infusion chemotherapy: a critical review. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Jabboury,et al.  Cis‐diamminedichloroplatinum (II) by 5‐day continuous infusion a new dose schedule with minimal toxicity , 1984, Cancer.

[5]  C. Kovacs,et al.  Proliferative defects in renal and intestinal epithelium after cis-dichlorodiammine platinum (II). , 1982, British journal of cancer.

[6]  H. Pinedo,et al.  Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration. , 1983, European journal of cancer & clinical oncology.

[7]  P. Lohman,et al.  Induction and repair of DNA cross-links in chinese hamster ovary cells treated with various platinum coordination compounds in relation to platinum binding to DNA, cytotoxicity, mutagenicity, and antitumor activity. , 1984, Cancer research.

[8]  S. Ito,et al.  Multiple and irreversible binding of cis-diamminedichloroplatinum(II) to human serum albumin and its effect on warfarin binding. , 1991, Chemical & pharmaceutical bulletin.

[9]  J. da Silva,et al.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.

[10]  D. Bajorin,et al.  Pharmacokinetics of cis-diamminedichloroplatinum(II) after administration in hypertonic saline. , 1986, Cancer research.

[11]  S. Steinberg,et al.  Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients. , 1990, Cancer research.

[12]  G Milano,et al.  Effects of prolonged exposure to cisplatin on cytotoxicity and intracellular drug concentration. , 1992, European journal of cancer.

[13]  H. Pinedo,et al.  Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. , 1982, European journal of cancer & clinical oncology.

[14]  J. Bertino,et al.  24‐Hour infusion of cis‐platinum in head and neck cancers , 1978, Cancer.

[15]  P A Dekker-de Kiefte,et al.  Diagnosis and Treatment , 2020, Diabetes.